Objective: We aimed to assess the role of edaravone on cisplatin-induced lung tissue damage.

Materials and Methods: 4 groups were formed using 40 Wistar albino rats. In group 1 (control group) (n=10), neither any drugs were given nor anything was performed. In group 2 (cisplatin group) (n=10), only 7.5 mg/kg cisplatin was given. In group 3 (edaravone group) (n=10), only 1 mg/kg edaravone was given. In group 4 (cisplatin+edaravone group) (n=10), 7.5 mg/kg cisplatin and 1 mg/kg edaravone were administered. Blood malondialdehyde (MDA) and nitric oxide (NO) levels were studied. Lungs were removed in all groups. Tissue damage was evaluated by using a light microscop. In addition, immunohistochemistry was used for evaluation.

Results: In the cisplatin group, MDA and NO levels were found to be higher than the other groups (p<0.05). Histopathologic damage was more prominent in the cisplatin group than other groups and the difference was statistically significant (p<0.05). Immunstaining with CD68 and bcl 2 were indicated that immunoexpression was significantly higher in the cisplatin group than cisplatin+ edaravone group.

Conclusion: According to our short-term findings, edaravone is effective in the prevention of cisplatin-induced lung injury.